Kuopio Atherosclerosis Prevention Study (KAPS)

Abstract

These data establish the antiatherogenic effect of LDL-C lowering by pravastatin in hypercholesterolemic men in a primary prevention setting and suggest a greater effect in smokers than in nonsmokers.